Effectiveness of a treatment algorithm for hemodialysis-associated pruritus in terms of changes in medications
Tóm tắt
Hemodialysis-associated pruritus (HAP) is a serious complication that occurs in 60–80% of hemodialysis patients, which not only decreases quality of life but also worsens prognosis. We have developed a treatment algorithm to take a comprehensive cause-specific approach to HAP and used it at our facility since June 2009. In this treatment algorithm, moisturizers and topical steroids are used depending on skin condition and severity of pruritus; administration of nalfurafine hydrochloride is considered in treatment-resistant cases. If pruritus improves, we attempt to taper topical steroids by switching to lower potency or by dose reduction or discontinuation. Here, we examined the effectiveness of the treatment algorithm over 9 years in terms of changes in medications. Subjects were hemodialysis patients who received treatment for HAP at our facility: 89 in May 2009 before introduction of the algorithm, and 131 in April 2013, 164 in October 2014, 190 in October 2015, 181 in October 2016, 215 in October 2017, and 224 patients in October 2018 after its introduction. A questionnaire survey was conducted on the presence of pruritus, severity (using a visual analogue scale [VAS] and Shiratori severity scores), frequency, and insomnia due to pruritus. Changes in medications were investigated using medical records and compared. The proportion of patients with pruritus decreased significantly from 96.6% in 2009 to 66.8% in 2018 (p < 0.001). Median VAS score significantly decreased from 53.0 mm in 2009 to 24.5 mm in 2018 (p < 0.001), and the proportion of patients with insomnia due to pruritus also significantly decreased from 25.8% in 2009 to 2.2% in 2018 (p < 0.001). The proportion of patients who used moisturizers significantly increased from 34.8 to 89.7% (p < 0.001). The proportion of patients receiving topical steroids decreased from 47.2 to 35.7%, but the difference was not significant (p = 0.085). The treatment algorithm was shown to be useful for improving HAP, but future challenges were identified, including promoting use of lower potency topical steroids or discontinuation. Further prospective studies are required to confirm the role of each treatment intervention in a comprehensive cause-specific approach to HAP.
Tài liệu tham khảo
Pisoni RL, Wikström B, Elder SJ, Akizawa T, Asano Y, Keen ML, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Transplant. 2006;21:3495–505.
Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69:1626–32.
Kimata N, Fuller DS, Saito A, Akizawa T, Fukuhara S, Pisoni RL, et al. Pruritus in hemodialysis patients: results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). Hemodial Int. 2014;18:657–67.
Remakrishnan K, Bond TC, Claxton A, Sood VC, Kootsikas M, Agnese W, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis. 2014;7:1–12.
Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, Smith M, et al. ITCH National Registry Investigators: a longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1410–9.
Shirazian S, Aina O, Park Y, Chowdhury N, Leger K, Hou L, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis. 2017;10:11–26.
Grochulska K, Ofenloch RF, Mettang T, Weisshaar E. Mortality of haemodialysis patients with and without chronic itch: a follow-up study of the German Epidemiological Hemodialysis Itch Study (GEHIS). Acta Derm Venereol. 2019;99:423–8.
Rayner HC, Larkina M, Wang M, Graham-Brown M, van der Veer SN, Ecder T, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12:2000–7.
Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017;70(5):638–55.
Suzuki H, Omata H, Kumagai H. Recent advances in treatment for uremic pruritus. Open J Nephrol. 2015;5:1–13.
Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87:685–91.
Takahashi N, Yoshizawa T, Kumagai J, Kawanishi H, Moriishi M, Masaki T, et al. Response of patients with hemodialysis-associated pruritus to new treatment protocol with nalfurafine hydrochloride: a retrospective survey-based study. Ren Replace Ther. 2016;2:27.
Japan Meteorological Agency. Historical weather data search [in Japanese]. https://www.data.jma.go.jp/obd/stats/etrn/index.php?prec_no=67&block_no=47765&year=2013&month=5&day=4&view. Accessed on February 22, 2021.
Bolanos CG, Pham NM, Mair RD, Meyer TW, Sirich TL. Metabolomic analysis of uremic pruritus in patients on hemodialysis. PLoS One. 2021;16(2):e0246765.
Yamada S, Sakurai H, Kasuga H, Kawahara H. Investigation of the status of uremic pruritus in hemodialysis patients and the efficacy of nalfurafine hydrochloride –questionnaire administered to 1,936 patients from 17 clinics in Tokai area of Japan. J Jpn Soc Dial Ther. 2012; 45(12): 1133-1140 (In Japanese).
Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, et al. Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018;48(3):E252–62.
Furue M, Ebata T, Ikoma A, Takeuchi S, Kataoka Y, Takamori K, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol. 2013;93:214–21.
Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798–804.
Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92:497–501.
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–7.
Shiratori A. Therapeutic outcomes of the use of mequitazine (LM-209) in severe dermatological diseases. Nishinihon J Dermatol. 1983; 45: 470-473. (in Japanese)
Masakane I. High-quality dialysis: a lesson from the Japanese experience. Nephrol Dial Transplant Plus. 2010;3(Suppl 1):i28–35.
Kato A, Takita T, Furuhashi M, Takahashi T, Watanabe T, Maruyama Y, et al. Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-α. Artif Organs. 2001;25:441–7.
Lin HH, Liu YL, Liu JH, Chou CY, Yang YF, Kuo HL, et al. Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs. 2008;32:468–72.
Aoike I. Clinical significance of protein adsorbable membranes―long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant. 2007;22:13–9.
Aucella F, Vigilante M, Gesuete A. Review: the effect of polymethylmethacrylate dialysis membranes on uraemic pruritus. Nephrol Dial Transplant Plus. 2010;3(Suppl 1):i8–11.
Uchiumi N, Sakuma K, Sato S, Matsumoto Y, Kobayashi H, Toriyabe K, et al. The clinical evaluation of novel polymethyl methacrylate membrane with a modified membrane surface: a multicenter pilot study. Ren Replace Ther. 2018;4:32.
Jiang X, Ji F, Chen ZW, Huang QL. Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. Int Urol Nephrol. 2016;48(9):1533–41.
Masakane I. How to prescribe hemodialysis or hemodiafiltraion in order to ameliorate dialysis-related symptoms and complications. Contrib Nephrol. 2011;168:53–63.
Sakurai K. Biomarkers for evaluation of clinical outcomes of hemodiafiltration. Blood Purif. 2013;35(Suppl 1):64–8.
Karkar A, Abdelrahman M, Locatelli F. A randomized trial on health-related patient satisfaction level with high-efficiency online hemodiafiltration versus high-flux dialysis. Blood Purif. 2015;40:84–91.
Takahashi N, Yoshizawa T, Tsuchiya S. Current status and treatment strategies of hemodialysis-associated pruritus. Contrib Nephrol. 2018;196:88–95.
Hattori A, Taguchi N, Ohtomo S, Kaburagi Y. General skin lesions in hemodialysis patients. Kitakanto Med J. 1987;37:539-547. (in Japanese)
Szepietowski JC, Reich A, Schwartz RA. Uremic xerosis. Nephrol Dial Transplant. 2004;19:2709–12.
Tominaga M, Ozawa S, Tengara S, Ogawa H, Takamori K. Intraepidermal nerve fibers increase in dry skin of acetone-treated mice. J Dermatol Sci. 2007;48:103–11.
Han L, Dong X. Itch mechanisms and circuits. Annu Rev Biophys. 2014;43:331–55.
Kiliç Akça N, Taşçi S. An important problem among hemodialysis patients: uremic pruritus and affecting factors. Turk J Nephrol. 2014;23:210–6.
Kamo A, Tominaga M, Negi O, Tengara S, Ogawa H, Takamori K. Topical application of emollients prevents dry skin-inducible intraepidermal nerve growth in acetone-treated mice. J Dermatol Sci. 2011;62:63–6.
Katoh N, Ooya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et. al.. Clinical practice guidelines for atopic dermatitis. Jpn J Dermatol. 2018;128(12):2431-2502. (in Japaenese)
Kumagai H, Saruta T, Matsukawa S, Utsumi J. Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. Itch: basic mechanisms and therapy. New York: Marcel Dekker; 2004. p. 279–86.
Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, et al. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo). 1998;46:366–9.
Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7.
Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol. 1998;111:297–301.
Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol. 2007;56:979–88.
Wieczorek A, Krajewski P, Kozioł-Gałczyńska M, Szepietowski JC. Opioid receptors expression in the skin of hemodialysis patients suffering from uremic pruritus. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16360.
Andoh T, Maki T, Li S, Uta D. β2-microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur J Pharmacol. 2017;810:134–40.
Wang CP, Lu YC, Tsai IT, Tang WH, Hsu CC, Hung WC, et al. Increased levels of total p -cresylsulfate are associated with pruritus in patients with chronic kidney disease. Dermatology. 2016;232:363–70.
Eusebio-Alpapara KMV, Castillo RL, Dofitas BL. Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. Int J Dermatol. 2020;59(4):412–22.
Feng W-W, Yuan B, Shen F-Y, Fan W-Y, Mei D-S, Bao B-Y, et al. Efficacy of uremic pruritus treatment in patients undergoing hemodialysis, a network meta-analysis for randomized clinical trials. Nephrol Ther. 2021;17(1):30–4.
Gao C-Q, Zhou J-J, Tan Y-Y, Tong C-J. Effectiveness of montelukast for uremic pruritus in hemodialysis patients: a protocol for systematic review and meta-analysis. Medicine. 2020;99(46):e23229.